Adherence to a predefined vaccination program in patients with inflammatory bowel disease.

[1]  Sempsph.  Calendario de vacunaciones sistemáticas del adulto y recomendaciones de vacunación para los adultos que presentan determinadas condiciones médicas, exposiciones, conductas de riesgo o situaciones especiales. Consenso 2014. , 2014 .

[2]  J. Lindsay,et al.  Factors associated with thiopurine non‐adherence in patients with inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[3]  Deborah A. Adams,et al.  Summary of Notifiable Diseases - United States, 2011. , 2013, MMWR. Morbidity and mortality weekly report.

[4]  J. Lindsay,et al.  Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease , 2012, Journal of pediatric gastroenterology and nutrition.

[5]  Abigail Shefer,et al.  Recommended Adult Immunization Schedule: United States, 2011* , 2011, Annals of Internal Medicine.

[6]  C. Kotton.  Vaccines and Inflammatory Bowel Disease , 2010, Digestive Diseases.

[7]  R. Horne,et al.  Factors Associated With Non-Adherence to Oral Medication for Inflammatory Bowel Disease: A Systematic Review , 2010, The American Journal of Gastroenterology.

[8]  P. Skolnik,et al.  A Practical Guide to Vaccinating the Inflammatory Bowel Disease Patient , 2010, The American Journal of Gastroenterology.

[9]  G. Melmed.  Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. , 2009, Inflammatory bowel diseases.

[10]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[11]  M. Esteve,et al.  Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[12]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[13]  Y. Yazdanpanah,et al.  Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis , 2007, Gut.

[14]  K. Mazzocco,et al.  Risk factors for non‐adherence to medication in inflammatory bowel disease patients , 2007, Alimentary pharmacology & therapeutics.

[15]  E. Cabré,et al.  Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease , 2006, Digestive Diseases and Sciences.

[16]  W. Sandborn,et al.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  S. Kane.  Systematic review: adherence issues in the treatment of ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[18]  H. Hattori.  Mucosal Prolapse Polyp Arising on the Anastomotic Site or Postpolypectomy Site of the Rectum Endoscopically Mimicking Recurrence of Adenocarcinoma , 2005, Digestive Diseases and Sciences.

[19]  A. Román,et al.  Adherence to treatment in inflammatory bowel disease. , 2005, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[20]  B. Sands,et al.  Guidelines for immunizations in patients with inflammatory bowel disease. , 2004, Inflammatory bowel diseases.

[21]  G. Triadafilopoulos,et al.  Communicating with patients with inflammatory bowel disease. , 2004, Inflammatory bowel diseases.

[22]  J. Lewis,et al.  Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. , 2003, Gastroenterology.

[23]  M. J. Shale,et al.  Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[24]  A. Cohen,et al.  Patient nonadherence to medication in inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[25]  A. Hungin,et al.  Long‐term aminosalicylate therapy is under‐used in patients with ulcerative colitis: a cross‐sectional survey , 2002, Alimentary pharmacology & therapeutics.

[26]  S. Hanauer,et al.  Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis , 2001, American Journal of Gastroenterology.

[27]  L. Holmberg,et al.  Survival and causes of death in patients with inflammatory bowel disease: a population-based study. , 1992, Gastroenterology.